CD8A and neoplasm: This could be achieved through various TLR9-dependent mechanisms, for instance by encouraging the differentiation of tumor-specific myeloid-derived suppressor cells to overcome their immunosuppressive effects and boost effector CD8+ T-cell activity [57], or by directly increasing cytokine production on tumor antigen-activated CD8+ T cells [27,58,59,60].